Wieland HA - Search Results

1

Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.

Michel MC, Gaida W, Beck-Sickinger AG, Wieland HA, Doods H, Dürr H, Jung G, Schnorrenberg G. Michel MC, et al. Among authors: wieland ha. Mol Pharmacol. 1992 Oct;42(4):642-8. Mol Pharmacol. 1992. PMID: 1331755

2

The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226.

Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth M, Wienen W, Beck-Sickinger AG, Doods HN. Rudolf K, et al. Among authors: wieland ha. Eur J Pharmacol. 1994 Dec 27;271(2-3):R11-3. doi: 10.1016/0014-2999(94)90822-2. Eur J Pharmacol. 1994. PMID: 7705422

3

BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist.

Doods H, Gaida W, Wieland HA, Dollinger H, Schnorrenberg G, Esser F, Engel W, Eberlein W, Rudolf K. Doods H, et al. Among authors: wieland ha. Eur J Pharmacol. 1999 Nov 19;384(2-3):R3-5. doi: 10.1016/s0014-2999(99)00650-0. Eur J Pharmacol. 1999. PMID: 10611450

4

Effects of the neuropeptide Y Y(2) receptor antagonist BIIE0246 on presynaptic inhibition by neuropeptide Y in rat hippocampal slices.

Weiser T, Wieland HA, Doods HN. Weiser T, et al. Among authors: wieland ha. Eur J Pharmacol. 2000 Sep 15;404(1-2):133-6. doi: 10.1016/s0014-2999(00)00478-7. Eur J Pharmacol. 2000. PMID: 10980271

5

Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor.

Cabrele C, Wieland HA, Koglin N, Stidsen C, Beck-Sickinger AG. Cabrele C, et al. Among authors: wieland ha. Biochemistry. 2002 Jun 25;41(25):8043-9. doi: 10.1021/bi0201421. Biochemistry. 2002. PMID: 12069595

6

Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226.

Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA. Doods HN, et al. Among authors: wieland ha. J Pharmacol Exp Ther. 1995 Oct;275(1):136-42. J Pharmacol Exp Ther. 1995. PMID: 7562541

7

Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.

Wieland HA, Willim KD, Entzeroth M, Wienen W, Rudolf K, Eberlein W, Engel W, Doods HN. Wieland HA, et al. J Pharmacol Exp Ther. 1995 Oct;275(1):143-9. J Pharmacol Exp Ther. 1995. PMID: 7562543

8

Labeling of neuropeptide Y receptors in SK-N-MC cells using the novel, nonpeptide Y1 receptor-selective antagonist [3H]BIBP3226.

Entzeroth M, Braunger H, Eberlein W, Engel W, Rudolf K, Wienen W, Wieland HA, Willim KD, Doods HN. Entzeroth M, et al. Among authors: wieland ha. Eur J Pharmacol. 1995 May 24;278(3):239-42. doi: 10.1016/0014-2999(95)00161-d. Eur J Pharmacol. 1995. PMID: 7589160

9

Adrenomedullin mediates vasodilation via CGRP1 receptors.

Entzeroth M, Doods HN, Wieland HA, Wienen W. Entzeroth M, et al. Among authors: wieland ha. Life Sci. 1995;56(1):PL19-25. doi: 10.1016/0024-3205(94)00412-l. Life Sci. 1995. PMID: 7830489

10

Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations.

Beck-Sickinger AG, Wieland HA, Wittneben H, Willim KD, Rudolf K, Jung G. Beck-Sickinger AG, et al. Among authors: wieland ha. Eur J Biochem. 1994 Nov 1;225(3):947-58. doi: 10.1111/j.1432-1033.1994.0947b.x. Eur J Biochem. 1994. PMID: 7957231 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters